NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Area of Science:

• Oncology
• Clinical Guidelines

Background:

• The National Comprehensive Cancer Network (NCCN) has published Breast Cancer Treatment Guidelines annually since 1996.
• Adjuvant therapy for breast cancer has rapidly evolved, necessitating expert review.

Purpose of the Study:

• To provide an extended discussion and expanded input for adjuvant therapy recommendations within the NCCN Breast Cancer Treatment Guidelines.
• To address evolving treatment strategies and incorporate new data into breast cancer care.

Main Methods:

• Formation of an Adjuvant Therapy Task Force, supplementing the NCCN Breast Cancer Guidelines Panel with additional experts.
• Discussion of risk-stratification methods for recurrence.
• Evaluation of biologic markers (HER2, estrogen receptor, genetic markers) as prognostic or predictive factors.
• Analysis of patient factors (age, menopausal status, estrogen receptor levels) influencing chemotherapy and endocrine therapy benefits.
• Review of aromatase inhibitor strategies for postmenopausal women and trastuzumab incorporation for HER2/neu-positive breast cancer.

Main Results:

• The task force provided a forum for in-depth discussion on complex adjuvant therapy issues.
• Recommendations were informed by the integration of risk stratification, biomarker data, and patient-specific factors.
• Strategies for novel therapies like aromatase inhibitors and trastuzumab were considered for inclusion.

Conclusions:

• The supplement summarizes the background data and discussions from the Adjuvant Task Force meeting.
• The expert discussions aim to refine and enhance the NCCN Breast Cancer Treatment Guidelines for adjuvant therapy.
• The evolving landscape of breast cancer treatment requires continuous expert evaluation and guideline updates.